QUIC: Immunotherapy, Chemotherapy Combination for Advanced BTC

Johnathan Ebben, MD, PhD, of University of Wisconsin Department of Medicine, and Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health, break down the design and importance of the QUIC study.

The phase 2 investigation looks at the efficacy of gemcitabine, cisplatin, quemliclustat, and zimberelimab for first-line treatment of advanced biliary tract cancers.